bioAffinity Technologies, Inc. Announces CEO Presentation at H.C. Wainwright Conference

bioAffinity Technologies, Inc. announced that its President and CEO, Maria Zannes, will present a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held from September 14-16, 2026. The presentation will cover strategic milestones, commercial progress of the CyPath® Lung diagnostic test, and advancements in the company's technology platform for developing new diagnostic and therapeutic applications. A live and archived webcast of the presentation will be available on September 11. The company also reported that as of September 2, 2026, there were 600,736 outstanding shares of common stock, with an aggregate market value of approximately $5.9 million.